Regorafenib Combination Therapy in Advanced Hepatocellular Carcinoma: With or without Transarterial Chemoembolization
Triple therapy demonstrated superior survival benefits compared to dual therapy in patients with advanced HCC. Additionally, the safety profiles of the two treatment regimens were comparable.
Authors
- X. D. Yu (ORCID: https://orcid.org/0000-0002-8584-7985)
- Haoqing Chen (ORCID: https://orcid.org/0000-0002-4290-6092)
- Yi Peng (ORCID: https://orcid.org/0000-0002-4268-1655)
- Yaben Liu
- Jinze Li
- Feng Ji (ORCID: https://orcid.org/0000-0002-2051-5453)
- Ping Xie (ORCID: https://orcid.org/0000-0002-0754-2959)
- Lu Gu (ORCID: https://orcid.org/0000-0003-2596-6891)
- Lei Cao (ORCID: https://orcid.org/0000-0002-6493-1467)
- Xiangyu Lu (ORCID: https://orcid.org/0000-0002-2095-6830)
Institutions
- University of Electronic Science and Technology of China (CN)
Publication Details
- Journal
- Oncology
- Published
- 2024-11-27
- DOI
- https://doi.org/10.1159/000542775
- Citations
- 1
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.37